With the recent announcement of a twice-daily medication for HIV prevention that shows 96% efficacy, I see a strong potential upside for GILD. This breakthrough could drive significant interest and capital towards the stock in the coming weeks.

I’ve been drawing lines on this stock on the 5 minute chart for 5 years. I believe the price hit a resistance at 74.43 and it will drop in the course of 2-3 days to the support level of 72.74.nThese are some skitzo type of lines.

Primary Biliary congitis received FDA accelerated approval this week. Ensuring cashflow of $4billionnfor current affected patients and all future patients by being the only valuable treatment for this disease. Not to mention $Gild has obesity drugs in the pipeline as well to catch up with the rest. Plus this giant has been accumulating for 5+years